EUVIMEDScopri EUVIMED
Multizentrische StudieBeobachtungsstudieOpen access · CC BY-NC 4.0

Impact of Pre‐Heart Transplant Levosimendan Administration on Post‐Transplant Vasoplegia and Primary Graft Dysfunction

Joan Guzman-Bofarull iD, Alba Martín-Centellas iD, David Couto-Mallon iD, Roger Borràs iD, Andrea Arenas-Loriente iD, Mercedes Rivas-Lasarte iD, Javier Segovia-Cubero iD, María G Crespo-Leiro iD, Ana García-Álvarez iD, Marta Farrero iD

Clinical Transplantation · 2025

DOI: 10.1111/ctr.70327 ↗

At a glance

Multizentrische Studie in Clinical Transplantation, 2025. Written by Joan Guzman-Bofarull and 9 co-authors. Institution: Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain. Major MEDLINE topics: Simendan, Vasoplegia, Heart Transplantation, Primary Graft Dysfunction. Cited 2 times so far (Crossref); 45 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares, Fundación Alfonso Martín Escudero, Sociedad Española de Cardiología.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Introduction

Levosimendan, a calcium‐sensitizing inotropic agent, is used in patients with advanced heart failure (HF) awaiting heart transplantation (HT). Its prolonged effects, due to an active metabolite, may influence post‐transplant vasodilation, particularly when administered shortly before HT. However, its impact on post‐HT complications such as vasoplegia and primary graft dysfunction (PGD) remains unclear. This study aimed to evaluate whether preoperative levosimendan affects these outcomes.

Methods

This retrospective, multicenter observational study included adult HT recipients from 2010 to 2022 across three Spanish centers. Patients were grouped based on whether they received levosimendan within 1 month prior to HT. Main outcomes were post‐HT vasoplegia (defined as cardiac index ≥2.5 L/min/m 2 , systemic vascular resistance 20 or norepinephrine administration >0.1 µg/kg/min at 24 h post‐HT) and severe PGD, as defined by the 2014 ISHLT criteria. Secondary outcomes included all‐cause mortality. Subgroup analyses were performed for patients receiving levosimendan within 1 week of HT and by sex. Statistical analyses included propensity score (PS) matching, Kaplan–Meier curves, and multivariate Cox regression models.

Results

Among 598 HT recipients, 94 (15.7%) received levosimendan preoperatively. After PS adjustment, no significant differences were found in the incidence of vasoplegia (40.0% vs. 39.2%, OR 0.99, p = 0.98) or severe PGD (10.6% vs. 10.3%, OR 1.25, p = 0.63) between groups. Post‐HT mortality was also not different (HR 0.78, p = 0.37). Vasoplegia did not affect mortality, while severe PGD was linked to higher mortality. Subgroup and sex‐based analyses revealed no significant outcome differences.

Conclusions

Pre‐HT levosimendan use was not associated with increased early post‐transplant complications and appears to be a safe strategy. Summary This study evaluated whether giving levosimendan before HT affects early post‐transplant complications. Among 598 patients, 94 received levosimendan within a month before surgery. Results showed no significant differences in rates of vasoplegia, severe primary graft dysfunction, or mortality. Levosimendan use appears safe in the immediate pre‐transplant setting.

Subjects

MeSH terms (MEDLINE)

SimendanVasoplegiaHeart TransplantationPrimary Graft DysfunctionPostoperative ComplicationsCardiotonic AgentsHeart FailureHumansFemaleMaleRetrospective StudiesMiddle AgedFollow-Up StudiesPrognosisRisk FactorsGraft SurvivalSurvival RateAdultPreoperative Care

Author keywords

heart transplantationlevosimendanprimary graft dysfunctionvasoplegia

Substances

SimendanCardiotonic Agents

Authors and institutions

  • Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain.
  • Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain.
  • Hospital Puerta de Hierro, Madrid, Spain.
  • Complejo Hospitalario Universitario De A Coruña (CHUAC), Instituto de Investigación Biomédica De A Coruña (INIBIC), A Coruña, Spain.
  • Centro De Investigación Biomédica En Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
  • Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.

ORCID profiles: Joan Guzman-Bofarull, Alba Martín-Centellas, David Couto-Mallon, Roger Borràs, Andrea Arenas-Loriente, Mercedes Rivas-Lasarte, Javier Segovia-Cubero, María G Crespo-Leiro, Ana García-Álvarez, Marta Farrero

Funding

  • Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares
  • Fundación Alfonso Martín Escudero
  • Sociedad Española de Cardiología

Cite

APA

Guzman-Bofarull, J., Martín-Centellas, A., Couto-Mallon, D., Borràs, R., Arenas-Loriente, A., Rivas-Lasarte, M., Segovia-Cubero, J., Crespo-Leiro, M. G., García-Álvarez, A., & Farrero, M. (2025). Impact of Pre‐Heart Transplant Levosimendan Administration on Post‐Transplant Vasoplegia and Primary Graft Dysfunction. Clinical Transplantation. https://doi.org/10.1111/ctr.70327

Vancouver

Guzman-Bofarull J, Martín-Centellas A, Couto-Mallon D, Borràs R, Arenas-Loriente A, Rivas-Lasarte M, et al. Impact of Pre‐Heart Transplant Levosimendan Administration on Post‐Transplant Vasoplegia and Primary Graft Dysfunction. Clinical Transplantation. 2025. doi:10.1111/ctr.70327

BibTeX
@article{GuzmanBofarull2025,
  author = {Guzman-Bofarull, Joan and Martín-Centellas, Alba and Couto-Mallon, David and Borràs, Roger and Arenas-Loriente, Andrea and Rivas-Lasarte, Mercedes and Segovia-Cubero, Javier and Crespo-Leiro, María G and García-Álvarez, Ana and Farrero, Marta},
  title = {Impact of Pre‐Heart Transplant Levosimendan Administration on Post‐Transplant Vasoplegia and Primary Graft Dysfunction},
  journal = {Clinical Transplantation},
  year = {2025},
  doi = {10.1111/ctr.70327}
}
Start for free →